


Eptifibatide

Cat. No.: HY-B0686
CAS No.: 188627-80-7
Molecular Formula: C₃₅H₄₉N₁₁O₉S₂
Molecular Weight: 831.96
Sequence: MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH₂
Sequence Shortening: MPA-HAR-GDWPC-NH₂
Target: Integrin
Pathway: Cytoskeleton
Storage: Sealed storage, away from moisture and light
 Powder -80°C 2 years
 -20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (300.50 mM; Need ultrasonic)
 H₂O : 50 mg/mL (60.10 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.2020 mL	6.0099 mL	12.0198 mL
	5 mM		0.2404 mL	1.2020 mL	2.4040 mL
	10 mM		0.1202 mL	0.6010 mL	1.2020 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
Solubility: 100 mg/mL (120.20 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor,

	with anti-platelet activity ^[1] .
In Vitro	Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Pharmacol Res. 2021 Mar 9;105540.
- Int J Mol Sci. 2021, 22(7), 3323.
- Rheinische Friedrich-Wilhelms-Universität Bonn. 2023 May 31.
- Faculty of Pharmaceutical Sciences. Ghent University. 2018 May.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42(8):703-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA